Bradley T. Andresen, PhD, FAHA
Associate Professor, Biotechnology and Pharmaceutical Sciences
College of Pharmacy
Phone: (909) 469-8483 | Fax: (909) 469-5600
Join year: 2011
BS
Hope College 1998
PhD
Unversity of Pittsburgh2002
Postdoc
NIH 2004
- GPCRs
- Signal transduction
- Hypertension
- Cancer
- Molecular Modeling
The Andresen laboratory is focused on three projects, all from a molecular pharmacology lens. Students in the lab will get to work on whichever project is currently active in the lab. If they are going to spend a significant amount of time in the lab, they can choose a project. Below is a brief description of the projects.
Cancer Prevention
Our group identified that the commercially available β-blocker carvedilol (Coreg®) has cancer-preventative properties. However, we do not know the cancer preventative mechanism of action. We hypothesize that carvedilol increases DNA repair. Students will learn DNA repair mechanisms and cell culture techniques to study DNA repair.
Drug Discovery
The Andresen lab has developed a screening method to hopefully enrich for agonists. We have 10 experimental agonists that need to be examined for activity and specificity. As this project grows, we hope to find agonists for the orphan GPCRs. This project is a combination of computer-based experiments to develop predictions and wet lab experiments to test the predictions. Currently, the project is in the first phase of the wet lab tests. Students will learn to examine GPCR signaling.
Kinetic control of GPCR signaling
Using a chimeric heterotrimeric G-protein, we have identified a novel mechanism controlling GPCR signaling. We hypothesize that RGS proteins can indirectly interfere with the function of GRKs. We will test the hypothesis through molecular and functional studies. Students will learn how to determine if two proteins interact with each other and examine GPCR signaling.
09/07/16 – 08/31/19 NSF - Major Research Instrumentation
PI: Michel Baudry Role: Co-PI
Funding $495,000
Title: MRI: Acquisition of a Confocal Microscope
This grant is a Major Research Instrumentation (MRI) program award that will establish a confocal core facility at WesternU. I am one of the key players in evaluating the bids from the manufactures.
06/14/18 – 05/31/21 NIH 1R15CA227946-01
PI: Ying Huang Role: Co-Investigator
Funding $409,223 Direct Costs: $295,511
Title: Topical Delivery of Non-β-blocking R-carvedilol for Prevention of UV-induced Skin Cancer
This grant aims to develop a topical formulation of R-carvedilol for the prevention of skin cancer.
Awards:
2019 Named as an Innovation Champion at WesternU
2014 Recognized for participating in the APS Professional Development Fellowship
2011 Elected as a Full Member of Sigma Xi, The Scientific Research Society
2007 Elected as a Fellow of the American Heart Association
2002 Society for Experimental Biology and Medicine Travel Fellowship to Experimental Biology
2001 Best Paper Award, Division of Cardiovascular Pharmacology, ASPET
2001 ASPET Travel Fellowship to Experimental Biology 2001
2000-2002 Dean’s Fellowship
1998-2000 Nation Institute of Health Pharmacology Training Grant Recipient
1997 American Heart Association Undergraduate Research Grant Recipient
1993 Participant in the Michigan State High School Honors Science Program
- 2011-present Sigma Xi
- 2011-present American Association of Colleges of Pharmacy (AACP)
- 2001-present American Heart Association (AHA), Council for High Blood Pressure Research
- 2000-present American Society for Pharmacology and Experimental Therapeutics (ASPET)
- 2000-present Society for Experimental Biology and Medicine (SEBM)
- 1998-present American Physiological Society (APS)
Committees:
Grant study sections
2022 AHA Transformational Project Award Basic Sciences 1 Peer Review Committee
2021 – 2024 AHA career Development Award Vascular 1 Committee
2021 Ad Hoc member of NIH MIST March study section
2019 AHA Transformational Project Award Basic Sciences 3 Peer Review Committee
2013 – 2017 AHA Vascular BioBP BSc1 Peer Review Committee
2010 – 2011 AHA Student Undergraduate Research Fellowship Peer Review Committee
Editorial Advisory Boards
2024 – present JPET Editor’s Choice Co-Editor
2021 – present Review Editor: Frontiers in Endocrinology – Cellular Endocrinology
Fall 2018 – present Journal of Pharmacology and Experimental Therapeutics (JPET)
2014 – present Review Editor: Frontiers in Regenerative Pharmacology
2011 – present Review Editor: Frontiers in Vascular Physiology
2008 – 2017 Journal of Pharmacology and Experimental Therapeutics (JPET)
Contribution to Professional Societies
2023 - 2026 Member of the ASPET Finance Committee
2021 Member of the ASPET SURF task force
2016 – 2021 Abstract grader for category 5.22, Ligand-Mediated Signaling and Receptor Pharmacology for the AHA Scientific Sessions
2015 – 2016 Member of the ASPET SURF task force
2015 – 2016 Member of the APS/PhysSoc programming committee
2014 – 2016 Member of the APS Joint Programming committee
2014 – 2016 Chair of the APS Translational Physiology Interest Group Programming Committee
2013 – 2015 Abstract grader for category 713, Receptor Pharmacology for the AHA Scientific Sessions
2012 – 2013 Member of the at large nomination committee for Sigma Xi
2009 – 2011 Member of the ASPET Web Advisory Committee
Community
2024 Judge for the Senior Zoology Section of the CA State Science Fair
2023 Judge for the Senior Zoology Section of the CA State Science Fair
2022 Judge for the Senior Biochemistry and Molecular Biology Section II of the CA State Science Fair
2021 Judge for the Mammalian Biology Section of the CA State Science Fair
2019 Judge for the Mammalian Biology Section of the CA State Science Fair
2016 Judge for the Toxicology Section of the CA State Science Fair
2015 Judge for the Mammalian Biology Section of the CA State Science Fair
2013 – 2014 Judge for the Pharmacology/Toxicology Section of the CA State Science Fair
2022 – present Participated in the ASPET Volunteer Day
2015 – 2019 Participated in the ASPET Volunteer Day at EB
2009 – 2013 Participated in the ASPET Volunteer Day at EB
2003 – 2007 National Library of Medicine guest speaker - I discussed pharmacology with student groups visiting the NLM.
2003 – 2004 NIH speakers’ bureau member
2016 Judge for the Toxicology Section of the CA State Science Fair
2015 Judge for the Mammalian Biology Section of the CA State Science Fair
2013-2014 Judge for the Pharmacology/Toxicology Section of the CA State Science Fair
2015-present Participated in the ASPET Volunteer day at EB
2009-2013 Participated in the ASPET Volunteer day at EB
2003- 2007 National Library of Medicine guest speaker
I discussed pharmacology with student groups visiting the NLM.
2003 -2004 NIH speakers’ bureau member
Here is my link for PubMed:
Below are some selected publications representative of current work within the laboratory:
Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL Jr,Andresen BT, Huang Y. Topically applied carvedilol attenuates solar ultraviolet radiation induced skin carcinogenesis. Cancer Prev. Res. 10:598-606, 2017. doi: 10.1158/1940-6207.CAPR-17-0132
Chang A, Yeung S, Thakkar A, Huang KM, Liu M, Kanassatega RS, Parsa C, Orlando R, Jackson EK,Andresen BT, Huang Y. Prevention of skin carcinogenesis by the β-blocker carvedilol. Cancer Prev. Res. 8:27-36, 2015.
Andresen BT. The basis of translational physiology: from molecules to humans, a wide arc of scientific inquiry. Physiology 30:4-5, 2015.
Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L, BastepeM, Jackson EK, and Andresen BT. The β-blocker Nebivolol is a GRK/β-arrestin Biased Agonist. PLoS ONE 8(8): e71980, 2013.
Nistala R, Pulakat L, Andresen BT, Sinak C, Mandavia C, Thekkumkara T, Speth R, Whaley-Connell A, and Sowers J. Angiotensin Type 1 Receptor Resistance To Blockade In The Opossum Proximal Tubule Cell Due To Variations In The Binding Pocket. Am J Physiol Renal Physiol 304:F1105, 2013.
Andresen BT. A pharmacological primer of biased agonism. Endocr Metab Immune Disord Drug Targets 11:92, 2011.
Andresen BT. Characterization of G protein-coupled receptor kinase 4 and measuring its constitutive activity in vivo. Methods Enzymol. 484:631, 2010.
Escano CS, Keever LB, Gutweiler AA,Andresen BT. Angiotensin II Activates ERK Through a Non-Receptor Tyrosine Kinase Dependent Mechanism in Renal Smooth Muscle Cells: Implications for Blood Pressure Regulation.J Pharmacol Exp Ther.324:34-42, 2008.
Keever LB, Jones JE,Andresen BT. G protein-coupled receptor kinase 4ginteracts with inactive Gas and Ga13.Biochem Biophys Res Commun.367:649-55, 2008